Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
4 minute read

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

By Vandana Singh
May 27, 9:43 AM
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.

BBIB

Read More
1 minute read

Coya Announces Acceptance Of Oral Presentation, “Regulatory T Cell Expansion Strategy To Target Inflammation In Alzheimer’s Disease: A Phase 1 Feasibility Study,” At The 18th International Conference On Alzheimer’s And Parkinson’s Disease In Lisbon

By Benzinga Newsdesk
October 27, 9:01 AM
Alireza Faridar, MD (Houston Methodist and Weill Cornell Medical College) will present data from an open-label, proof-of-concept study in 8 AD patients treated with Low Dose IL-2 (LD IL-2) over a 4 month period that

COYA

Read More
1 minute read

Coya Therapeutics Announces The Presentation Of Human Ex-Vivo Mechanistic Data Further Supporting The Development Of COYA 302 For Amyotrophic Lateral Sclerosis At The 22nd Annual Northeast ALS Consortium Meeting

By Benzinga Newsdesk
October 3, 9:06 AM
The scientific poster highlights the role of pro-inflammatory macrophages and monocytes in reducing regulatory T cell (Treg) immunomodulatory suppressive function and the anti-inflammatory effect of Treg-enhancing

COYA

Read More
2 minute read

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes With CTLA-4 Protein To Selectively Target Immune Cells With Potential To Deliver Targeted Therapies Across Multiple Diseases

By Happy Mohamed
September 7, 9:26 AM
Using proprietary exosome tethering modification technology, Treg derived exosomes were engineered with a surface protein, cytotoxic T lymphocyte associated protein 4 (CTLA-4) to increase selective targeting to immune

COYA

Read More
2 minute read

Coya Therapeutics Announces Publication Of Potential Novel Blood Biomarker Data In Amyotrophic Lateral Sclerosis Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell Enhancing Therapies

By Happy Mohamed
August 31, 8:01 AM
Pathological hallmarks of ALS are characterized by alterations in inflammation and oxidative stress, with oxidative stress playing a critical role in neuronal damage. 4-hydroxy-2-nonenal (4-HNE) is a key mediator of

COYA